[ad_1] Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Vaccinating one million adults ages 65 and above with a single RSV shot from Pfizer or GSK may prevent thousands of hospitalizations over two seasons of the virus, according to a Centers for Disease Control and Prevention analysis. A CDC medical officer presented the…
[ad_1] The first vaccines to guard against the respiratory illness RSV could soon be available for older adults, ages 60 and over, after a panel of advisers to the Centers for Disease Control and Prevention voted in support of them Wednesday. Their vote, during the first of a three-day meeting of the CDC’s Advisory Committee…
[ad_1] A health worker prepares a flu vaccine shot before administering it to a local resident in Los Angeles, the United States, on Dec. 17, 2022. Xinhua News Agency | Getty Images An advisory committee to the Centers for Disease Control and Prevention on Wednesday recommended that adults ages 60 and above, after consulting their…
[ad_1] Pfizer‘s vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer’s clinical trial on more than 34,000 older adults over two RSV seasons. The latest data is specifically on…
[ad_1] Respiratory syncytial virus viral vaccine under research. Hailshadow | Istock | Getty Images GlaxoSmithKline on Wednesday said its vaccine to protect adults ages 60 and older from respiratory syncytial virus, or RSV, remained effective across two seasons of the disease. A single dose of the shot was 67.2% effective in preventing lower respiratory tract…
[ad_1] Luis Alvarez | Digitalvision | Getty Images The Food and Drug Administration on Wednesday approved a vaccine made by Pfizer that protects adults ages 60 and older from respiratory syncytial virus, a common pathogen that kills and hospitalizes thousands of seniors every year. Pfizer, in a statement Wednesday, said it expects to have supply…
[ad_1] A pharmacist prepares to administer COVID-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois. Scott Olson | Getty Images Three years and billions of Covid vaccinations into the pandemic, Pfizer and Moderna say their work is…
[ad_1] Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images The Food and Drug Administration’s independent panel of advisors on Thursday recommended full approval of Pfizer’s vaccine that protects infants from RSV, but raised safety concerns over premature births that may be tied to the shot. The committee unanimously said…
[ad_1] Blood sample for respiratory syncytial virus (RSV) test Jarun011 | Istock | Getty Images U.S. Food and Drug Administration staff on Tuesday said Pfizer’s vaccine that protects infants from respiratory syncytial virus has “generally favorable” safety data. The FDA staff made the conclusion in briefing documents ahead of a meeting on Thursday, when a…
[ad_1] A GSK lab in London. Oli Scarff | Getty Images The Food and Drug Administration on Wednesday approved an RSV vaccine produced by GlaxoSmithKline for use on adults ages 60 and older. The approval, the first ever globally by a regulatory body for an RSV vaccine, is a decisive victory for GSK in a…
